Pacific Shuanglin Bio-pharmacy Co

Pacific Shuanglin Bio-pharmacy Co FCF Margin

The Free Cash Flow Margin of Pacific Shuanglin Bio-pharmacy Co (000403.SZ) as of Oct 29, 2026 is -20.87 %. In the previous year, Free Cash Flow Margin was -7.49 % — a change of 178.50% (lower).

FCF Margin

-20.87 %

YoY

178.50%

Last updated:

Free Cash Flow Margin of Pacific Shuanglin Bio-pharmacy Co is 2025 -20.87 % . Free Cash Flow Margin of Pacific Shuanglin Bio-pharmacy Co was 2024 -7.49 % . It decreases by 178.50% lower compared to the previous year.

The Pacific Shuanglin Bio-pharmacy Co FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
9.49 CNY
Jan 1, 2019
16.35 CNY
Jan 1, 2020
14.73 CNY
Jan 1, 2021
4.16 CNY
Jan 1, 2022
6.05 CNY
Jan 1, 2023
12.96 CNY
Jan 1, 2024
-7.49 CNY
Jan 1, 2025
-20.87 CNY
The Pacific Shuanglin Bio-pharmacy Co FCF Margin history
YEARFCF MarginYoY
-20.87 %+178.50%
-7.49 %-157.83%
12.96 %+114.08%
6.05 %+45.43%
4.16 %-71.75%
14.73 %-9.92%
16.35 %+72.28%
9.49 %-185.84%
-11.06 %+74.59%
-6.33 %-390.25%
2.18 %+78.32%
1.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pacific Shuanglin Bio-pharmacy Co Stock analysis

What does Pacific Shuanglin Bio-pharmacy Co do? Pacific Shuanglin Bio-pharmacy Co., Ltd. generates revenue through the production and marketing of pharmaceutical products including human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin. The company targets domestic healthcare providers and hospitals within China as its primary customers. Its core business focuses on supplying essential therapeutic products for medical treatment and patient care. The firm operates exclusively within the domestic Chinese market without international expansion. The company's product portfolio consists of specialized immunoglobulins and blood-derived therapeutic agents. These products serve critical medical needs such as immune support, infection prevention, and treatment of specific diseases. Domestic hospitals and healthcare institutions are the primary buyers of these pharmaceutical solutions. The business model relies on consistent domestic demand for these specialized medical products. Pacific Shuanglin Bio-pharmacy's revenue streams are derived from the sale of its core pharmaceutical products to Chinese healthcare facilities. The domestic market remains the sole operational focus, with no indication of international sales or additional product lines beyond those listed. The company's workforce of 2,093 full-time employees supports this focused production and distribution model. Pacific Shuanglin Bio-pharmacy Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pacific Shuanglin Bio-pharmacy Co stock

Free Cash Flow Margin of Pacific Shuanglin Bio-pharmacy Co is -20.87 % in 2025.

Free Cash Flow Margin of Pacific Shuanglin Bio-pharmacy Co changed from -7.49 % to -20.87 %, representing a 178.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Pacific Shuanglin Bio-pharmacy Co since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Pacific Shuanglin Bio-pharmacy Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pacific Shuanglin Bio-pharmacy Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pacific Shuanglin Bio-pharmacy Co